1. Home
  2. NVO

as 12-05-2024 1:41pm EST

$
-
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Founded: 1923 Country:
Denmark
Denmark
Employees: N/A City: N/A
Market Cap: 530.0B IPO Year: N/A
Target Price: $144.20 AVG Volume (30 days): 5.9M
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield:
1.32%
Dividend Payout Frequency: Semi-Annual
EPS: 3.17 EPS Growth: 26.84
52 Week Low/High: $94.73 - $148.15 Next Earning Date: 01-29-2025
Revenue: $40,469,178,712 Revenue Growth: 26.15%
Revenue Growth (this year): 25.02% Revenue Growth (next year): 20.47%

NVO Daily Stock ML Predictions

Share on Social Networks:

Similar to NVO Stocks: